1. Home
  2. CNXC vs VRDN Comparison

CNXC vs VRDN Comparison

Compare CNXC & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Concentrix Corporation

CNXC

Concentrix Corporation

HOLD

Current Price

$27.27

Market Cap

2.1B

Sector

Technology

ML Signal

HOLD

Logo Viridian Therapeutics Inc.

VRDN

Viridian Therapeutics Inc.

HOLD

Current Price

$18.82

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNXC
VRDN
Founded
1991
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.7B
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
CNXC
VRDN
Price
$27.27
$18.82
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
13
Target Price
$54.80
$38.25
AVG Volume (30 Days)
1.7M
1.8M
Earning Date
03-24-2026
05-05-2026
Dividend Yield
5.42%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$9,825,771,000.00
$5,706,000.00
Revenue This Year
$5.17
$27.65
Revenue Next Year
$2.51
$253.29
P/E Ratio
N/A
N/A
Revenue Growth
2.15
N/A
52 Week Low
$24.27
$9.90
52 Week High
$62.14
$34.29

Technical Indicators

Market Signals
Indicator
CNXC
VRDN
Relative Strength Index (RSI) 41.03 23.68
Support Level $24.27 $17.91
Resistance Level $34.64 $19.42
Average True Range (ATR) 2.23 1.12
MACD -0.20 -1.02
Stochastic Oscillator 29.84 13.93

Price Performance

Historical Comparison
CNXC
VRDN

About CNXC Concentrix Corporation

Concentrix Corp is a technology and services company. It designs, implements, and manages end-to-end solutions, including customer experience process optimization, technology development and design engineering, front- and back-office automation, analytics, and business transformation services. The company serves clients across multiple industry verticals, helping them manage customer engagement and operational processes throughout the customer lifecycle. The company operates in a single operating segment. It generates revenue through the provision of technology and services under contractual arrangements. Geographically, the company generates the maximum revenue from the Philippines and the rest from India, the United States, Great Britain, Germany, Canada and Other countries.

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Share on Social Networks: